Full-Time

Manufacturing Training Specialist

Manufacturing Support

Updated on 9/13/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$107.5k - $145.5k/yr

Holly Springs, NC, USA

In Person

Bachelor's, Master's, PhD, Associate's

Category
Training (1)
Required Skills
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master’s degree in chemistry, biology, or engineering plus 3 years of biotechnology operations experience, or a bachelor’s degree plus 5 years of biotechnology operations experience, or an associate’s degree plus 10 years of biotechnology operations experience, or a high school diploma/GED plus 12 years of biotechnology operations experience.
Responsibilities
  • Develop and execute the manufacturing training strategy for ANC-1 and ANC-2, aligning it with business objectives, operational readiness requirements, compliance expectations, and workforce capability needs.
  • Create, implement, and continuously mature the Training Assignment Portfolio for ANC-1 and ANC-2 to establish role-based qualification pathways and improve training effectiveness.
  • Develop and maintain training and workforce readiness governance tools, metrics, and reporting processes covering training compliance, qualification status, staffing readiness, procedural readiness, and manufacturing startup readiness.
  • Identify readiness risks and gaps through metric review, stakeholder input, and floor engagement, then drive mitigation actions for operational readiness milestones, engineering runs, validation execution, and startup commitments.
  • Escalate and resolve issues when training, qualification, staffing, procedures, or other manufacturing readiness deliverables threaten startup milestones or operational readiness commitments.
  • Align hiring plans, qualification plans, readiness milestones, engineering runs, and validation execution to prepare the manufacturing workforce for ANC-2 startup and routine operations.
  • Lead Manufacturing Fundamentals Training programs for onboarding and qualification of new hires in the ANC-1 and ANC-2 organizations.
  • Serve as the training lead for the 2027 Learning Management System migration, supporting planning, implementation, change management, training impact assessments, and platform adoption.
  • Lead training improvement initiatives across manufacturing operations.
  • Own and implement training-related corrective and preventive actions, including timely execution, effectiveness monitoring, and sustained compliance.
  • Assess training effectiveness and identify opportunities to strengthen workforce capability, procedural adherence, and operational performance.
  • Develop and deliver technical training programs, including the Wake Tech Customized Training Program.
  • Coach manufacturing personnel and frontline leaders on good manufacturing practice compliance, operational excellence practices, and manufacturing best practices.
  • Partner with Manufacturing, Quality, Engineering, and Continuous Improvement teams to establish and maintain training curricula supporting process changes, operational excellence initiatives, and inspection readiness.
  • Maintain a strong manufacturing-floor presence to provide training support, coaching, and technical assistance to frontline teams and leaders.
  • Serve as a subject matter expert for Learning Management System and training-related processes in manufacturing.
  • Partner with operations teams to identify and implement training improvements that enhance safety, quality, delivery, and productivity.
  • Drive right-first-time execution through Human and Organizational Performance tools and operator feedback collection.
  • Partner with Quality, Engineering, Validation, Supply Chain, Human Resources, and Manufacturing teams to achieve site objectives and maintain integrated readiness plans.
  • Influence stakeholders at multiple organizational levels to drive alignment, resolve issues, and implement sustainable solutions.
  • Represent Manufacturing in ANC-2 Operational Readiness governance and planning activities, ensuring workforce readiness, qualification execution, and startup risks are visible, aligned, and actively managed.
  • Provide data-driven recommendations, readiness metric insights, and risk-based mitigation options to support business decisions, issue resolution, and operational readiness governance.
Desired Qualifications
  • Hands-on experience facilitating problem solving in a biotechnology environment.
  • Experience with training development and facilitation.
  • Experience owning and editing standard operating procedures.
  • Familiarity with deviation management systems and corrective/preventive actions.
  • Project management skills with the ability to multitask and function in a dynamic environment.
  • Excellent communication skills and a sense of urgency.
  • Demonstrated ability to forge and maintain strong relationships.
  • Strong knowledge of Learning Management Systems.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.